Cargando…
Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study
BACKGROUND: The present study aimed to comprehensively investigate the occurrence and risk factors of adverse events (AEs) or adverse drug reactions (ADRs) (especially for thrombocytopenia and bleeding) in Chinese female patients receiving bivalirudin during percutaneous coronary intervention (PCI)....
Autores principales: | Wu, Fan, Liu, Xueying, Ran, Huazhong, Tang, Qiwei, Zhong, Cheng, Wu, Yanqing, Xiao, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851799/ https://www.ncbi.nlm.nih.gov/pubmed/35172721 http://dx.doi.org/10.1186/s12872-022-02474-3 |
Ejemplares similares
-
Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006) -
Safety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Ahmad Hamdi, Abdul Hafeez, et al.
Publicado: (2017) -
Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study
por: Guo, Yanqing, et al.
Publicado: (2023) -
Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Liu, Xiao-Qiang, et al.
Publicado: (2020) -
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
por: Ramana, Ravi K, et al.
Publicado: (2008)